Pfizer to buy King Pharmaceuticals
The drug giant will expand its offerings by buying the pain-treatment company for $3.6 billion.
By Adam Feuerstein, TheStreet
The deal values King at $14.25 a share, or a 40% premium over King's closing price of $10.15 a share Monday. Pfizer said the acquisition will have no material impact on 2010 earnings but will add approximately 2 cents a share to estimated 2011 and 2012 earnings.
King specializes in pain drugs, including Embeda, an opioid that's resistant to abuse and misuse. King earned $1.10 a share in 2009 on total revenue of $1.78 billion and is expected to earn 68 cents a share on $1.48 billion this year, according to Thomson Reuters.
Pfizer said the King acquisition will allow it to expand its current pain offerings, which include Lyrica and Celebrex.
Pfizer shares were down 5 cents to $17.33 in premarket trading.
Copyright © 2014 Microsoft. All rights reserved.
[BRIEFING.COM] The S&P 500 ran into a wall of resistance shortly after the top of the hour and dipped back to its lows of the morning (which weren't all that low). The pullback was emblematic of today's session where there simply hasn't been much conviction.
The latter is raising a few eyebrows since there was enough good news this morning (eg., no escalation of geopolitical problems, M&A activity, ISM Index at highest level since March 2011) to power up the market, and yet ... More
More Market News
|There’s a problem getting this information right now. Please try again later.|
VIDEO ON MSN MONEY
MUST-SEE ON MSN
- Video: Easy DIY smoked meats at home
A charcuterie master shares his process for cold-smoking meat at home.
- Jetpacks about to go mainstream
- Weird things covered by home insurance
- Bing: 70 percent of adults report 'digital eye strain'